SENORESNSESENORES PHARMACEUTICALS LLowNeutral
Announced Mon, 27 Jul · 15:17 IST

Q1 FY27 results: Revenue up 36%, PAT up 56% YoY; SMP categorized

Board & Shareholder Meetings View source PDF

SENORES · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
1-day move
₹1388.00
prior close
₹1441.20
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-2.5-2.8
Up moveDown movePending
AI summary

Board approved Q1 FY27 unaudited results (quarter ended June 30, 2026). Revenue rose 36% YoY to Rs 180.21 crores. EBITDA up 87% YoY to about Rs 54 crores, with around 800 bps margin expansion. Net profit grew about 56% YoY to Rs 30.72 crores. Basic EPS at Rs 6.60 vs Rs 4.60. Regulated Markets revenue up 42%. ANDA portfolio nearly doubled to 58. Also categorized Ms. Anjali Shah as Senior Management Personnel from July 27, 2026.

Likely market impact

Strong Q1 with double-digit revenue and profit growth plus sharp margin expansion. SMP change is routine. Stock may react favorably.